Synlett 2015; 26(12): 1764-1768
DOI: 10.1055/s-0034-1380218
letter
© Georg Thieme Verlag Stuttgart · New York

Facile Synthesis of 2,4-Disubstituted Thiooxazoles and 2,4-Disubstituted Oxazole Sulfonyl Chlorides via Acyl Isothiocyanates and TMS-Diazomethane

John I. Trujillo*
Pfizer Worldwide R&D, Eastern Point Road, Groton, CT 06340, USA   Email: john.i.trujillo@pfizer.com
,
Eric P. Arnold
Pfizer Worldwide R&D, Eastern Point Road, Groton, CT 06340, USA   Email: john.i.trujillo@pfizer.com
,
Steve Kortum
Pfizer Worldwide R&D, Eastern Point Road, Groton, CT 06340, USA   Email: john.i.trujillo@pfizer.com
,
Ralph P. Robinson
Pfizer Worldwide R&D, Eastern Point Road, Groton, CT 06340, USA   Email: john.i.trujillo@pfizer.com
› Author Affiliations
Further Information

Publication History

Received: 18 March 2015

Accepted after revision: 23 April 2015

Publication Date:
01 June 2015 (online)


Abstract

An expedient method for the direct conversion of acyl isothiocyanates to 2,4-disubstitued thiooxazoles and 2,4-disubstituted oxazole sulfonyl chlorides is described. The method takes advantage of an early observation by Sheehan and the reaction of diazomethane with isocyanates to form oxazolones. However, in this case an acyl isothiocyanate is utilized as well as the readily available TMS-diazomethane to provide access to the desired 4-substituted sulfur derivatives. The 2,4-disubstituted oxazole systems synthesized represent novel thiooxazoles and oxazole sulfonyl chlorides not previously described.

Supporting Information

 
  • References and Notes

    • 1a Ortwine DF, Aliagas I. Mol. Pharmaceutics 2013; 10: 1153
    • 1b Meanwell N. Chem. Res. Toxicol. 2011; 24: 1420
    • 1c Metabolism, Pharmacokinetics and Toxicity of Functional Groups. Smith D. RSC Publishing; Cambridge: 2010
    • 1d TPSA (Topical Polar Surface Area) PropCalc v2.41.
    • 1e cSFlogD (prediction of distribution coefficient (logD) in octanol/buffer at pH 7.4) Pfizer Internal Model
    • 2a Azman AM, Mullins RJ In Heterocyclic Chemistry in Drug Discovery . Li JJ. Wiley; New York: 2013: 231-281
    • 2b Khartulyari A, Maier ME. Knowledge Updates . In Science of Synthesis Vol. 3 . Thieme; Stuttgart: 2011: 57
  • 3 For the preparation of 2,4-disubstituted oxazole carboxylate derivatives, see: Graham T. Org. Lett. 2010; 12: 3614 ; and references cited therein

    • For previous reports of 2,4-disubstituted oxazole thio derivatives [SO2Ar, SMe, and SAr (c,d), respectively], see:
    • 4a Mortensen DS, Perrin-Ninkovic SM, Harris R, Lee BG. S, Shevlin G, Hickman M, Khambatta G, Bisonette RR, Fultz KE, Sankar S. Bioorg. Med. Chem. Lett. 2011; 21: 6793
    • 4b DeMartino JK, Garfunkle J, Hochstatter DG, Cravatt BF, Boger DL. Bioorg. Med. Chem. Lett. 2008; 18: 5842
    • 4c Schroeder R, Schoellkopf U, Blume E, Hoppe I. Justus Liebigs. Ann. Chem. 1975; 3: 533
    • 4d Schoellkopf U, Blume E. Tetrahedron Lett. 1973; 9: 629
  • 5 Sheehan JC, Izzo PT. J. Am. Chem. Soc. 1949; 71: 4059

    • For examples in the synthesis of oxazole-containing natural products, see:
    • 6a Smith III AB, Verhoest PR, Minbiole KP, Schelhaas M. J. Am. Chem. Soc. 2001; 123: 4834
    • 6b Smith III AB, Minbiole KP, Verhoest PR, Schelhaas M. J. Am. Chem. Soc. 2001; 123: 10942

      For synthesis of 2,4-substituted oxazole derivatives using triflate, see:
    • 7a Hoffman TJ, Rigby JH, Arseniyadis S, Cossy J. J. Org. Chem. 2008; 73: 2400
    • 7b Flegeau EF, Popkin ME, Greaney MF. Org. Lett. 2006; 8: 2495
    • 7c Langille NF, Dakin LA, Panek JS. Org. Lett. 2002; 4: 2485
    • 7d Smith III AB, Minbiole KP, Freeze S. Synlett 2001; 1739
    • 7e Barrett AG. M, Kohrt JT. Synlett 1995; 415

      For applications of triflate in the synthesis of druglike compounds, see:
    • 8a Chobanian H, Lin L, Liu P, Chioda MD, Devita RJ, Nargund RP, Guo Y. US 20110021531, 2011
    • 8b Huang Z, Jin J, Machajewski TD, Antonious-McCrea WR, McKenna M, Poon D, Renhowe PA, Sendzik M, Shafer CM, Smith A, Xu Y, Zhang Q. WO 2009115572, 2009
    • 8c Reiter LA, Freeman-Cook KD. PCT 2003090752, 2003

      For representative examples of aryl triflate to aryl-SR, see:
    • 9a Itoh T, Mase T. Org. Lett. 2004; 6: 4587
    • 9b Zheng N, McWilliams JC, Fleitz FJ, Armstrong III JD, Volante RP. J. Org. Chem. 1998; 63: 9606 ; Note: To our knowledge, no reactions of oxazole triflate/halo to oxazole-SR have been described in the literature

      For reactions of diazospecies with acyl isothiocyanates and isothiocyanates, respectively, see:
    • 10a Regitz M, Weber B, Heydt A. Liebigs Ann. Chem. 1980; 305
    • 10b Martin D, Mucke W. Justus Liebigs Ann. Chem. 1965; 682: 90
    • 11a Shiori T, Aoyama T, Snowden T In Handbook of Reagents for Organic Synthesis: Reagents for Silicon-Mediated Organic Synthesis. Fuchs PL. Wiley; New York: 2011: 590-598
    • 11b Heydt H. Science of Synthesis. Vol. 27. Thieme; Stuttgart: 2014: 843
    • 12a Alternatively, an aqueous workup followed by treatment of crude material with 1 M TBAF in THF (1.0 equiv) facilitated removal of TMS group at 5-position of the oxazole.
    • 12b A portion of the remaining mass balance is 5-silyl derivative (ca. 5%), while the remainder is undetermined.
  • 13 Skinner GS, Vogt HC. J. Am. Chem. Soc. 1955; 77: 5440
    • 14a Lowe D. Med. Chem. Commun. 2015; 6: 12
    • 14b Reymond JL, Ruddigkeit L, Awale M. Comput. Chemogenomics 2014; 39

      For recent reports of Ar/HetAr-SO2NHR/SO2Cl, see:
    • 15a Emmet EJ, Hayter BR, Willis MC. Angew. Chem. Int. Ed. 2014; 53: 10204
    • 15b Johnson MW, Bagley SW, Mankad NP, Bergman RG, Mascitti V, Toste FD. Angew. Chem. Int. Ed. 2014; 53: 4404
    • 15c Shavnya A, Coffey SB, Smith AC, Mascitti V. Org. Lett. 2013; 15: 6226
    • 15d DeBergh JR, Niljianskul N, Buchwald SL. J. Am. Chem. Soc. 2013; 135: 10638
  • 16 For a recent report of 2,4,5-trisubstituted oxazole sulfonyl chloride, see: Kornienko AN, Pil’o SG, Prokopenko VM, Brovarets VS. Russ. J. Gen. Chem. 2014; 84: 686
  • 17 General Procedure for Preparation of SBn Derivatives To a solution of benzoylisothiocyanate (500 mg, 3.06 mmol) in CH2Cl2 (15.0 mL, 0.12 M) cooled to 0 °C (ice-water bath) for 15 min was added TMSCHN2 (2 M in hexanes, 2.30 mL, 4.60 mmol, 1.5 equiv) slowly. The mixture became orange upon addition. After stirring for 1 h at 0 °C a yellow suspension was evident. To the mixture was slowly added DBU (0.92 mL, 6.13 mmol, 2.0 equiv), followed by the addition of BnBr (0.36 mL, 3.06 mmol) at which time the color dissipated. The reaction allowed to warm to ambient temperature and stirred overnight. The reaction was diluted with CH2Cl2 (10 mL) and then washed with brine, dried (Na2SO4), and the solvent removed to give a residue. The residue was diluted with CH2Cl2 (10 mL) and HCl in Et2O (2 M) was added (5 mL). Note: This was done to ensure removal of TMS group at the 5-position, which was approximately 20% by GC–MS. Alternatively, use of TBAF (2 M in THF was also used). The mixture was stirred for 3 h and then portioned between brine and CH2Cl2. The layers were separated and organic phase washed with brine, dried (Na2SO4), and the solvent removed to give a residue, which was purified by chromatography (silica, 12 g RediSep Column Gold, EtOAc–heptane, 0–40%, 15 CVs) to give the desired product 4-(benzylthio)-2-phenyloxazole (362 mg, 44%) as an oil and N-(1,2,3-thiadiazol-5-yl)benzamide (138 mg, 22%). 4-(Benzylthio)-2-phenyloxazole (12, Table 1 and 14a, Table 2, entry 1) 1H NMR (400 MHz, CDCl3): δ = 8.02–8.09 (m, 2 H), 7.44–7.52 (m, 3 H), 7.43 (s, 1 H), 7.20–7.33 (m, 5 H), 4.12 (s, 2 H) ppm. 13C NMR (101 MHz, CDCl3): δ = 162.2, 139.4, 137.7, 134.3, 130.7, 130.2, 129.1, 128.9, 128.8, 128.4, 127.2, 127.1, 126.5, 38.6 ppm. ESI-HRMS: m/z calcd for C16H13NOS [M + H]+: 268.0791; found: 268.0791 N-(1,2,3-thiadiazol-5-yl)benzamide (13) 1H NMR (400 MHz, DMSO-d 6): δ = 12.76 (br s, 1 H) 8.85 (s, 1 H) 8.08 (d, J = 7.81 Hz, 2 H) 7.50–7.81 (m, 3 H). 13C NMR (125 MHz, DMSO-d 6): δ = 164.7, 151.1, 136.2, 133.2, 130.9, 128.9, 128.1 ppm. ESI-HRMS: m/z calcd for C9H7N3OS [M + H]+: 206.0388; found: 206.0382.
  • 18 General Procedure for Preparation of SO2Cl Derivatives To a solution of 4-(benzylthio)-2-phenyloxazole (347.2 mg, 1.3 mmol) in AcOH (2 mL) was added H2O (0.5 mL). The reaction was cooled with an ice-water bath. After 10 min, NCS (538 mg, 4.03 mmol) was added in three portions. The reaction was stirred for 15 min at 0 °C and then allowed to stir at ambient temperature for 2 h. Solids were present when the flask was removed from the cooling bath, which subsequently dissolved upon warming. The yellow homogeneous solution was partitioned between brine and EtOAc. The layers were separated, and the organic phase washed with brine, dried (Na2SO4), and the solvent removed to give a residue. The residue was purified by chromatography (silica, 4 g Redisep Gold, EtOAc–heptane, 0–55%, 48 CVs) to give the desired product 2-phenyloxazole-4-sulfonyl chloride (240 mg, 76%) as a solid. 2-Phenyloxazole-4-sulfonyl Chloride (14b, Table 2, entry 1) 1H NMR (400 MHz, CDCl3): δ = 8.40 (s, 1 H), 8.12–8.19 (m, 2 H), 7.52–7.65 (m, 3 H). 13C NMR (101 MHz, CDCl3): δ = 163.5, 144.8, 141.7, 133.7, 132.4, 130.2, 129.1, 128.5, 128.2, 127.3, 125.1. ESI-HRMS: m/z calcd for C9H6ClNO3S [M + H]+: 243.983; found: 243.9829.